H o m e H o m e

m y S t a g e D x m y S t a g e D x

A b o u t A b o u t

N e w s N e w s

C a r e e r s C a r e e r s

Contact
Paramétrage des cookies

These cookies are necessary for the proper functioning of the site. They cannot be deactivated.

These cookies enable us to measure the number of visits, visitors and sources of traffic to our site (content of paths, etc.), and to compile statistics in order to improve its quality, ergonomics and performance.

Marketing cookies are used to track visitors through websites. The aim is to display ads that are relevant and interesting to the individual user and therefore more valuable to third-party publishers and advertisers.

This site uses cookies to improve our services. By clicking on “accept”, you agree to the use of all cookies.
Go back

Spotlight Medical Secures IVDR CE Marking for myStage Dx, Its AI-Enabled Prognostic Test for ER+/HER2 – Early Breast Cancer

23 Jun 2026
Press release

Class C software-only IVD supports European rollout of a JCO-published assay designed to bring clinically validated prognostic assessment into routine breast cancer care.

Read more

Read more news

06 Sep 2025

(French) Cancer du sein : l’IA au service de la désescalade thérapeutique

02 Sep 2025

(French) Cancers du sein : comment limiter l’escalade thérapeutique

25 Aug 2025

Spotlight Medical Announces Publication in Journal of Clinical Oncology Validating AI Pathology Assay That Identifies Low-Risk Subgroup Within Clinically High-Risk Early ER+/HER2- Breast Cancer

No results

© Spotlight Medical 2026